Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans
BIOLOGICAL PSYCHIATRY(2019)
摘要
Vasopressin modulates threat responses in pre-clinical studies, but until recently has been difficult to study in humans. We tested the effects of SRX246, a novel V1a-antagonist by Azevan Pharmaceuticals, Inc., on a translational paradigm of fear (phasic response to predictable threat) and anxiety (sustained response to unpredictable threat).
更多查看译文
关键词
Vasopressin 1a Receptor Antagonist,Startle,Anxiety & PTSD,Phase II Clinical Trial,Threat of Shock
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要